REGISTER
How single-agent Dato-DXd may reshape clinical pathways in triple-negative breast cancer
Prof. Gong and Prof. Trapani discussed how single-agent Dato-DXd may reshape clinical pathways in triple-negative breast cancer (TNBC) following the TROPION-Breast 02 study.

Prof. Chengcheng Gong, Fudan University Shanghai Cancer Center, China
Prof. Dario Trapani, European Institute of Oncology, Italy

Prof. Gong and Prof. Trapani discussed how single-agent Dato-DXd may reshape clinical pathways in triple-negative breast cancer (TNBC) following the TROPION-Breast 02 study. They explored the significance of TNBC entering the first-line ADC era, and shared perspectives on how the study findings may influence treatment sequencing, clinical decision-making, and the future role of ADCs in frontline management.

0
0
Loading